chevron_leftBack
As of 6 June 2026, D. Western Therapeutics Institute, Inc. has a market cap of $32.4M USD, ranking #33727 globally and #3216 in Japan.
It ranks #3052 in the Healthcare sector, and #1044 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$32.4MUSD
5.19B JPY
Enterprise Value
$25.48MUSD
4.08B JPY
Revenue (TTM)
$2.42MUSD
387.0M JPY
EBITDA (TTM)
-$3.58MUSD
-573.0M JPY
Net Income (TTM)
-$3.95MUSD
-632.0M JPY
EBITDA Margin
-148%
Profit Margin
-163%
PS Ratio
13.4
PB Ratio
3.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yuichi Hidaka
open_in_new
Employees
19
Founded
1999
Website
dwti.co.jp
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.1% | -1.1% | -6.3% | -11% | -13% | -17% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4576
株式会社デ・ウエスタン・セラピテクス研究所
ISIN: JP3548740004
Shares Out.:
Shares Outstanding:
57.472M1
Shares Float:
50.088M2
|
90 JPY | |
|
6DW
株式会社デ・ウエスタン・セラピテクス研究所
ISIN: JP3548740004
|
0.4400 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About D. Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TSE: 4519
|
$81.66B
252K%
13.07T JPY
|
28.9
|
|
TSE: 4502
|
$52.21B
161K%
8.36T JPY
|
75.1
|
|
TSE: 4578
|
$36.84B
114K%
5.9T JPY
|
15.7
|
|
TSE: 4568
|
$30.37B
94K%
4.86T JPY
|
16.2
|
|
TSE: 4503
|
$25.82B
80K%
4.13T JPY
|
14.2
|
|
TSE: 4507
|
$16.91B
52K%
2.71T JPY
|
13.9
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
SIX: RO
|
$324.68B
1M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
893K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
856K%
218.9B CHF
|
20.5
|
chevron_leftBack